Evidence map›Paper›PMID 39239358›Full record

ArticleHealth psychology and behavioral medicine2024

The Seattle Amyotrophic Lateral Sclerosis (ALS) Patient Project Database: observational, longitudinal, dyadic characterization of people with ALS and their partners.

Suzanne C Segerstrom, Edward J Kasarskis

Abstract read
In one paragraph

Article in Health psychology and behavioral medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Suzanne C SegerstromSchool of Human Development and Family Sciences, Oregon State University, Corvallis, OR, USA.ORCID https://orcid.org/0000-0002-4020-111X
Edward J KasarskisDepartment of Neurology, University of Kentucky College of Medicine, Lexington, KY, USA.ORCID https://orcid.org/0000-0001-5584-7506

Funding

Efficacy of NSCs in an EAE model of MSR16NS129748 · NINDS · OAKLAND UNIVERSITY · PI CHAUDHRY, G. RASUL · 2022 to 2025
$600k
Curation of the Seattle ALS PatientR03NS128748 · NINDS · UNIVERSITY OF KENTUCKY · PI SEGERSTROM, SUZANNE C. · 2022 to 2022
$153k
NINDS NIH HHS R03 NS128748NINDS NIH HHS R16 NS129748
6 · The paper itself

Abstract

Introduction: The median survival time in ALS is approximately 3 years, but survival times range from less than a year to more than 10 years and much variance in disease course remains to be explained. As is true for physical outcomes, there is considerable variance in QOL, which is influenced by psychological health, coping, and social support, among other psychosocial factors. The Seattle ALS Patient Project Database (SALSPPD) provides a unique opportunity for researchers to address established and novel hypotheses about disease progression and QOL in ALS. Methods: The SALSPPD is a longitudinal dataset of people with ALS ( Results: The provided data dictionary includes details of the over 500 variables measured in the study, which have been subsetted into domain datasets. Domains address physical, psychological, social, and behavioral status on the person with ALS and their partners. Missing data were coded according to their mechanism. Data are available in two formats: The Discussion: The SALSPPD will provide a rich resource to scientists interested in the natural history of ALS, psychosocial effects on ALS outcomes and vice versa, and psychosocial and disease outcomes of treatments.

Indexed as

dyadiclongitudinalNeurologyprogressionquality of life

Identifiers

PMID39239358
PMCPMC11376292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.